Seventeen's producer Bumzu is highest-earning K-pop songwriter of 2023: Komca
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Bumzu, producer of boy band Seventeen, was the highest-earning songwriter for K-pop in 2023, the Korea Music Copyright Association (Komca) said Monday.
Bumzu was awarded the Grand Prize at the 10th Komca Award held the same day.
The annual Komca Award, which takes place every February, honors the composer and lyricist who each earned the most copyright income from their work in the previous year, as well as other achievements such as the best rearrangement and most-streamed song.
The Grand Prize is given to the creator who grossed the highest income with their copyrighted music in the previous year. The prize was given to BTS music producer Pdogg for five straight years from 2019.
"Bumzu produced most of the songs for singers at his agency Pledis Entertainment, including Seventeen and NU'EST, and played a major role in bringing the K-pop genre to the global mainstream market."
Songwriter Cho Young-soo was awarded for the best rearrangement for the fourth running year and the sixth year in total.
Children's songwriter Lee Sang-hee was awarded in the Dongyo, or children's song, section, for the fourth straight year.
Songwriter and pianist Yiruma was given a prize in the classical music section for the third year and Han Tae-soo won the guggak (traditional Korean music) category.
The award for most-streamed song of 2023 went to trot singer Lim Young-woong's "Our Blues, Our Life" (2023).
BY YOON SO-YEON [yoon.soyeon@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Late actor Lee Sun-kyun honored at Screen Actors Guild Awards
- ‘I might ruin it’: Why Son Heung-min refused to sign a Korean fan's shirt
- Samsung stockpiling billions in cash for huge acquisition
- [단독] ‘세븐’ 아니라 ‘나인’ 이었다…현대차 12월 ‘아이오닉 9’ 출시
- S.Tiger, K-pop producer, 40, found dead on Friday
- New 'Value-up' plan to tackle 'Korea discount' lacks enforcement bite
- Inspire Arena looks to change the concertgoing experience in Korea
- Presidential office defends medical school quota hike
- [EXCLUSIVE] Hyundai to launch Ioniq 9 in December
- [단독] “제약 업계에선 미중 갈등 영향 없을 것” 글로벌 4위, 중국 우시바이오 CEO의 자신감